Pharma CBD Cannabinoid Research

Pharma CBD Research Dashboard

110

Primary Studies

35

Related Studies

145

Total Studies

Clinical Studies

17

Clinical Meta-analyses

18

Double-blind Clinical Trials

25

Clinical Trials

Pre-Clinical Studies

45

Meta-analyses/Reviews

3

Animal Studies

2

Laboratory Studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 145 studies associated with Pharma CBD.

Here is a small sampling of Pharma CBD studies by title:


Components of the Pharma CBD Research Dashboard

  • Top medical conditions associated with Pharma CBD
  • Proven effects in clinical trials for Pharma CBD
  • Receptors associated with Pharma CBD
  • Individual study details for Pharma CBD

Ready to become a subscriber? Go to our PRICING page.

Select New Cannabinoid

Filter Cannabinoid

Members can filter by the following criteria:

  • Study Type
  • Organ Systems
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Pharma CBD

Description of Pharma CBD

Pharmacologically produced products containing CBD correspond to a cannabis chemotype III. They represent a class of drugs that are produced and standardized from either man-made or plant-based materials.


The Federal Drug Administration (FDR) approved (June 25, 2018) a pharmaceutical version of CBD (Epidiolex) for marketing in the treatment of a couple of rare pediatric seizure disorders (Lennox-Gastaut syndrome and Dravet sundrome).

Other Names:

Pharmaceutical CBD

Epidiolex, Cannabidiol, (-)-Cannabidiol, (-)-trans-Cannabidiol


IUPAC Name: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol


Molecular Formula: C21H30O2


Source– PubChem

Pharma CBD Properties and Effects

Only Members can view Properties and Effects information. See DEMO page.

Pharma CBD Receptor Binding

Only Members can view Receptor Binding information. See DEMO page.

Disclaimer
Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own licensed physician or other medical professional. You should not use the information contained herein for diagnosing or treating a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.